临床可比性与欧洲生物类似药法规 - Suppr

Clinical comparability and European biosimilar regulations.

作者信息

Schellekens Huub, Moors Ellen

机构信息

Huub Schellekens is in the Departments of Pharmaceutical Sciences and Innovation Studies, Utrecht University, Utrecht, The Netherlands.

出版信息

Nat Biotechnol. 2010 Jan;28(1):28-31. doi: 10.1038/nbt0110-28.

DOI:10.1038/nbt0110-28

PMID:20062035

Abstract

摘要

相似文献

Clinical comparability and European biosimilar regulations.

Nat Biotechnol. 2010 Jan;28(1):28-31. doi: 10.1038/nbt0110-28.

In support of the European Union biosimilar framework.

Nat Biotechnol. 2012 Aug;30(8):745-8; author reply 748-9. doi: 10.1038/nbt.2322.

The place of pharmacokinetics in drug development in several European countries with respect to official regulations.

Int J Clin Pharmacol Biopharm. 1975 Jul;12(1-2):295-300.

J Biopharm Stat. 2014;24(6):1154-64. doi: 10.1080/10543406.2014.941994.

Non-clinical safety studies on biosimilar recombinant human erythropoietin.

Basic Clin Pharmacol Toxicol. 2007 Feb;100(2):73-83. doi: 10.1111/j.1742-7843.2007.00028.x.

Drug marketing exclusivity under United States and European Union law.

Food Drug Law J. 2004;59(4):479-518.

[Excipients: regulatory aspects].

Therapie. 1999 Jan-Feb;54(1):15-9.

Nat Rev Drug Discov. 2014 Feb;13(2):99-100. doi: 10.1038/nrd4210. Epub 2014 Jan 21.

J Biopharm Stat. 2010 Jan;20(1):3-9. doi: 10.1080/10543400903549892.

Understanding the biosimilar approval and extrapolation process-A case study of an epoetin biosimilar.

Crit Rev Oncol Hematol. 2016 Aug;104:98-107. doi: 10.1016/j.critrevonc.2016.04.016. Epub 2016 May 20.

引用本文的文献

A Regulatory Perspective on Biosimilar Medicines.

Pharmaceutics. 2024 Feb 25;16(3):321. doi: 10.3390/pharmaceutics16030321.

Indian J Endocrinol Metab. 2019 Jul-Aug;23(4):400-406. doi: 10.4103/ijem.IJEM_180_19.

Readability assessment of package leaflets of biosimilars.

BMJ Open. 2019 Jan 17;9(1):e024837. doi: 10.1136/bmjopen-2018-024837.

World J Clin Cases. 2018 Aug 16;6(8):161-166. doi: 10.12998/wjcc.v6.i8.161.

Development and 10-year history of a biosimilar: the example of Binocrit.

Ther Adv Med Oncol. 2018 Apr 17;10:1758835918768419. doi: 10.1177/1758835918768419. eCollection 2018.

Clin Drug Investig. 2018 Jun;38(6):481-490. doi: 10.1007/s40261-018-0637-1.

BioDrugs. 2018 Apr;32(2):129-135. doi: 10.1007/s40259-018-0262-9.

Assessment of structural and functional similarity of biosimilar products: Rituximab as a case study.

MAbs. 2018 Jan;10(1):143-158. doi: 10.1080/19420862.2017.1402996. Epub 2017 Dec 7.

Recent advances in (therapeutic protein) drug development.

F1000Res. 2017 Feb 7;6:113. doi: 10.12688/f1000research.9970.1. eCollection 2017.

Hybrid mass spectrometry approaches in glycoprotein analysis and their usage in scoring biosimilarity.

Nat Commun. 2016 Nov 8;7:13397. doi: 10.1038/ncomms13397.

本文引用的文献

Glatiramer acetate: evidence for a dual mechanism of action.

J Neurol. 2008 Mar;255 Suppl 1:26-36. doi: 10.1007/s00415-008-1005-5.

Nephrology (Carlton). 2006 Aug;11(4):341-6. doi: 10.1111/j.1440-1797.2006.00594.x.

Follow-on biologics: challenges of the "next generation".

Nephrol Dial Transplant. 2005 May;20 Suppl 4:iv31-36. doi: 10.1093/ndt/gfh1085.

Biotechnology and drug discovery: from bench to bedside.

South Med J. 2003 Dec;96(12):1174-86. doi: 10.1097/01.SMJ.0000066654.35645.F7.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Clinical comparability and European biosimilar regulations.

Nat Biotechnol. 2010 Jan;28(1):28-31. doi: 10.1038/nbt0110-28.

In support of the European Union biosimilar framework.

Nat Biotechnol. 2012 Aug;30(8):745-8; author reply 748-9. doi: 10.1038/nbt.2322.

The place of pharmacokinetics in drug development in several European countries with respect to official regulations.

Int J Clin Pharmacol Biopharm. 1975 Jul;12(1-2):295-300.

J Biopharm Stat. 2014;24(6):1154-64. doi: 10.1080/10543406.2014.941994.

Non-clinical safety studies on biosimilar recombinant human erythropoietin.

Basic Clin Pharmacol Toxicol. 2007 Feb;100(2):73-83. doi: 10.1111/j.1742-7843.2007.00028.x.

Drug marketing exclusivity under United States and European Union law.

Food Drug Law J. 2004;59(4):479-518.

[Excipients: regulatory aspects].

Therapie. 1999 Jan-Feb;54(1):15-9.

Nat Rev Drug Discov. 2014 Feb;13(2):99-100. doi: 10.1038/nrd4210. Epub 2014 Jan 21.

J Biopharm Stat. 2010 Jan;20(1):3-9. doi: 10.1080/10543400903549892.

Understanding the biosimilar approval and extrapolation process-A case study of an epoetin biosimilar.

Crit Rev Oncol Hematol. 2016 Aug;104:98-107. doi: 10.1016/j.critrevonc.2016.04.016. Epub 2016 May 20.

引用本文的文献

A Regulatory Perspective on Biosimilar Medicines.

Pharmaceutics. 2024 Feb 25;16(3):321. doi: 10.3390/pharmaceutics16030321.

Indian J Endocrinol Metab. 2019 Jul-Aug;23(4):400-406. doi: 10.4103/ijem.IJEM_180_19.

Readability assessment of package leaflets of biosimilars.

BMJ Open. 2019 Jan 17;9(1):e024837. doi: 10.1136/bmjopen-2018-024837.

World J Clin Cases. 2018 Aug 16;6(8):161-166. doi: 10.12998/wjcc.v6.i8.161.

Development and 10-year history of a biosimilar: the example of Binocrit.

Ther Adv Med Oncol. 2018 Apr 17;10:1758835918768419. doi: 10.1177/1758835918768419. eCollection 2018.

Clin Drug Investig. 2018 Jun;38(6):481-490. doi: 10.1007/s40261-018-0637-1.

BioDrugs. 2018 Apr;32(2):129-135. doi: 10.1007/s40259-018-0262-9.

Assessment of structural and functional similarity of biosimilar products: Rituximab as a case study.

MAbs. 2018 Jan;10(1):143-158. doi: 10.1080/19420862.2017.1402996. Epub 2017 Dec 7.

Recent advances in (therapeutic protein) drug development.

F1000Res. 2017 Feb 7;6:113. doi: 10.12688/f1000research.9970.1. eCollection 2017.

Hybrid mass spectrometry approaches in glycoprotein analysis and their usage in scoring biosimilarity.

Nat Commun. 2016 Nov 8;7:13397. doi: 10.1038/ncomms13397.

本文引用的文献

Glatiramer acetate: evidence for a dual mechanism of action.

J Neurol. 2008 Mar;255 Suppl 1:26-36. doi: 10.1007/s00415-008-1005-5.

Nephrology (Carlton). 2006 Aug;11(4):341-6. doi: 10.1111/j.1440-1797.2006.00594.x.

Follow-on biologics: challenges of the "next generation".

Nephrol Dial Transplant. 2005 May;20 Suppl 4:iv31-36. doi: 10.1093/ndt/gfh1085.

Biotechnology and drug discovery: from bench to bedside.

South Med J. 2003 Dec;96(12):1174-86. doi: 10.1097/01.SMJ.0000066654.35645.F7.

Clinical comparability and European biosimilar regulations.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献